- Drug Therapy
- Dietary Management
Congenital Hyperinsulinism Market was valued at USD 182 million in 2022 and is poised to grow at a CAGR of 5.5% over 2023-2029. Congenital hyperinsulinism (CHI or HI), refers to a variety of congenital disorders which is characterized by inappropriate and unregulated insulin secretion from the beta-cells of the pancreas, causing Hyperinsulinaemic hypoglycaemia (HH), and the most common cause of severe CHI are mutations in ABCC8 and KCNJ11 genes. Based on the treatment type, the drug therapy segment’s Octreotide is anticipated to dominate the market share over the forecast period. According to the National Organization for Rare Disorders, the incidence of congenital hyperinsulinism is approximately 1/25,000 to 1/50,000 births. Growing awareness about congenital hyperinsulinism and the increased R&D activities for the development of novel therapies will act as the congenital hyperinsulinism market growth drivers. However, the high cost of treatment would be the restraining factor for the market. Advancements in diagnostic techniques and novel approaches to minimize side effects are opportunities for key players in the market for the expansion of the market.
Fastest Growing Market
Initiatives by government and non-government organizations to create awareness of congenital hyperinsulinism treatment and increasing investments by pharmaceutical companies will impact the growth of the market. For example, Congenital Hyperinsulism International, focused on providing support such as disease diagnosis and disease management to the patient with CHI, held a family conference, in August 2022. For instance, in March 2022, Zealand Pharma completed a phase-III clinical trial for Dasiglucagon to control blood sugar in infants with congenital hyperinsulinism. Moreover, the other emerging therapies, such as RZ358, CSI-Glucagon, Pasireotide, and others will participate in the growth of the market. Thus, the increased awareness, research, and development for rare disorders will lead to the growth of the market within the forecast period. However, without the proper line of treatment for the disease, the growth of the market could get hampered.
The Congenital Hyperinsulinism market was valued at USD 182 million in 2022 and is expected to grow at a 5.5% CAGR over the forecast period 2023 – 2029.
Advancements in diagnostic techniques and novel approaches to minimize side effects are the key opportunities for the Congenital Hyperinsulinism market.
Growing awareness about congenital hyperinsulinism and the increased R&D activities for the development of novel therapies are the growth drivers in the Congenital Hyperinsulinism market.
Eli Lilly, IVAX Pharmaceuticals, Teva Pharmaceuticals, Novo Nordisk, Novartis AG, Rezolute, Inc., Xeris Pharmaceuticals, Eiger BioPharmaceuticals., Zealand Pharma A/S, Hanmi Pharmaceutical Co., Ltd., Crinetics Pharmaceuticals, Inc., and AmideBio LLC are a few companies operating in the Congenital Hyperinsulinism market.